Last reviewed · How we verify
SBR759A
SBR759A is a small molecule that targets the PI3K pathway.
SBR759A is a small molecule that targets the PI3K pathway. Used for Metastatic breast cancer, Metastatic colorectal cancer.
At a glance
| Generic name | SBR759A |
|---|---|
| Sponsor | Novartis |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SBR759A works by inhibiting the PI3K enzyme, which is involved in cell signaling and proliferation. This inhibition can lead to anti-tumor effects in various types of cancer.
Approved indications
- Metastatic breast cancer
- Metastatic colorectal cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |